TQSCAS# 353483-92-8 |
- Celastrol
Catalog No.:BCN5986
CAS No.:34157-83-0
- BMS-345541
Catalog No.:BCC1423
CAS No.:547757-23-3
- Bay 65-1942 free base
Catalog No.:BCC1408
CAS No.:600734-02-9
- Bay 65-1942 HCl salt
Catalog No.:BCC1409
CAS No.:600734-06-3
- Bay 65-1942 R form
Catalog No.:BCC1410
CAS No.:758683-21-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 353483-92-8 | SDF | Download SDF |
PubChem ID | 5038679 | Appearance | Powder |
Formula | C22H20N2O2S | M.Wt | 376.47 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 50 mM in DMSO | ||
Chemical Name | 4-naphthalen-1-yl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide | ||
SMILES | C1C=CC2C1C(NC3=C2C=C(C=C3)S(=O)(=O)N)C4=CC=CC5=CC=CC=C54 | ||
Standard InChIKey | SIZWDJIHABLBSP-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C22H20N2O2S/c23-27(25,26)15-11-12-21-20(13-15)17-8-4-10-19(17)22(24-21)18-9-3-6-14-5-1-2-7-16(14)18/h1-9,11-13,17,19,22,24H,10H2,(H2,23,25,26) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Type II positive allosteric modulator of α7 nACh receptors (pEC50 = 5.5). Displays no agonist activity at α7 receptors at concentrations up to 0.1 mM; potentiates agonist-evoked responses and reduces rate of desensitization of α7 nAChRs. Exhibits potency and efficacy similar to PNU 120596. |
TQS Dilution Calculator
TQS Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.6563 mL | 13.2813 mL | 26.5625 mL | 53.1251 mL | 66.4064 mL |
5 mM | 0.5313 mL | 2.6563 mL | 5.3125 mL | 10.625 mL | 13.2813 mL |
10 mM | 0.2656 mL | 1.3281 mL | 2.6563 mL | 5.3125 mL | 6.6406 mL |
50 mM | 0.0531 mL | 0.2656 mL | 0.5313 mL | 1.0625 mL | 1.3281 mL |
100 mM | 0.0266 mL | 0.1328 mL | 0.2656 mL | 0.5313 mL | 0.6641 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Monocrotaline N-oxide
Catalog No.:BCN2097
CAS No.:35337-98-5
- S26948
Catalog No.:BCC7751
CAS No.:353280-43-0
- NS 6180
Catalog No.:BCC6307
CAS No.:353262-04-1
- LY 487379 hydrochloride
Catalog No.:BCC7627
CAS No.:353229-59-1
- D-Alaninol
Catalog No.:BCC2728
CAS No.:35320-23-1
- (E)-3-Hydroxy-5-methoxystilbene
Catalog No.:BCN5292
CAS No.:35302-70-6
- Ziyuglycoside II
Catalog No.:BCN5291
CAS No.:35286-59-0
- Ziyuglycoside I
Catalog No.:BCN5290
CAS No.:35286-58-9
- 1-Chloroindan
Catalog No.:BCN2244
CAS No.:35275-62-8
- Caesalmin B
Catalog No.:BCN7252
CAS No.:352658-23-2
- Delafloxacin meglumine
Catalog No.:BCC1523
CAS No.:352458-37-8
- 9-Methoxy-alpha-lapachone
Catalog No.:BCN5289
CAS No.:35241-80-6
- 9-Hydroxycalabaxanthone
Catalog No.:BCN5293
CAS No.:35349-68-9
- HLM006474
Catalog No.:BCC5403
CAS No.:353519-63-8
- Honokiol
Catalog No.:BCN1001
CAS No.:35354-74-6
- J 113863
Catalog No.:BCC7422
CAS No.:353791-85-2
- Norathyriol
Catalog No.:BCN5294
CAS No.:3542-72-1
- 1-Methyl-5-nitro-1H-benzimidazole-2-butanoic acid ethyl ester
Catalog No.:BCC8470
CAS No.:3543-72-4
- 1-Methyl-5-amino-1H-benzimidazole-2-butanoic acid ethyl ester
Catalog No.:BCC8469
CAS No.:3543-73-5
- 5-[Bis(2-hydroxyethyl)amino]-1-methyl-1H-benzimidazole-2-butanoic acid ethyl ester
Catalog No.:BCC8724
CAS No.:3543-74-6
- Bendamustine HCl
Catalog No.:BCC1153
CAS No.:3543-75-7
- INO-1001
Catalog No.:BCC2212
CAS No.:3544-24-9
- Caraphenol A
Catalog No.:BCN5295
CAS No.:354553-35-8
- Hirsuteine
Catalog No.:BCN2756
CAS No.:35467-43-7
The impact of total quality service (TQS) on healthcare and patient satisfaction: an empirical study of Turkish private and public hospitals.[Pubmed:23494819]
Int J Health Plann Manage. 2014 Jul-Sep;29(3):292-315.
This paper attempts to measure patients' perceptions of the quality of services in public and private healthcare centers in Turkey. The main aim was to examine the impact of the dimensions of patient-perceived total quality service (TQS) on patients' satisfaction. The research framework and hypotheses are derived from a literature review of service quality and quality in the healthcare industry. The research data were collected through questionnaires and then statistically analyzed using descriptive statistics, Pearson product moment correlation and linear regression. The results suggest that service quality perceptions positively influence patient satisfaction with overall hospital care (SOHC). The most important factors identified in the regression model regarding patient SOHC are the quality of the hospital's social responsibility, administrative processes and overall experience of medical care received. These factors explain 74% of the variance in SOHC. The findings of the study can be used to improve TQS in both private and public hospitals.
Expeditious synthesis, enantiomeric resolution, and enantiomer functional characterization of (4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide (4BP-TQS): an allosteric agonist-positive allosteric modulator of alpha7 nicotinic acetylcholine receptors.[Pubmed:24090443]
J Med Chem. 2013 Nov 14;56(21):8943-7.
An expeditious microwave-assisted synthesis of 4BP-TQS, its enantiomeric separation, and their functional evaluation is reported. Electrophysiological characterization in Xenopus oocytes revealed that activity exclusively resided in the (+)-enantiomer 1b (GAT107) and (-)-enantiomer 1a did not affect its activity when coapplied. X-ray crystallography studies revealed the absolute stereochemistry of 1b to be 3aR,4S,9bS. 1b represents the most potent ago-PAM of alpha7 nAChRs available to date and is considered for further in vivo evaluation.
Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes.[Pubmed:17565004]
Mol Pharmacol. 2007 Sep;72(3):715-24.
Selective modulation of alpha7 nicotinic acetylcholine receptors (nAChRs) is thought to regulate processes impaired in schizophrenia, Alzheimer's disease, and other dementias. One approach to target alpha7 nAChRs is by positive allosteric modulation. Structurally diverse compounds, including PNU-120596, 4-naphthalene-1-yl-3a,4,5,9b-tetrahydro-3-H-cyclopenta[c]quinoline-8-sulfonic acid amide (TQS), and 5-hydroxyindole (5-HI) have been identified as positive allosteric modulators (PAMs), but their receptor interactions and pharmacological profiles remain to be fully elucidated. In this study, we investigated interactions of these compounds at human alpha7 nAChRs, expressed in Xenopus laevis oocytes, along with genistein, a tyrosine kinase inhibitor. Genistein was found to function as a PAM. Two types of PAM profiles were observed. 5-HI and genistein predominantly affected the apparent peak current (type I) whereas PNU-120596 and TQS increased the apparent peak current and evoked a distinct weakly decaying current (type II). Concentration-responses to agonists [ACh, 3-[(3E)-3-[(2,4-dimethoxyphenyl)methylidene]-5,6-dihydro-4H-pyridin-2-yl]pyridine dihydrochloride (GTS-21), and N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride (PNU-282987)] were potentiated by both types, although type II PAMs had greater effects. When applied after alpha7 nAChRs were desensitized, type II, but not type I, PAMs could reactivate alpha7 currents. Both types of PAMs also increased the ACh-evoked alpha7 window currents, with type II PAMs generally showing larger potentiation. None of the PAMs tested increased nicotine-evoked Ca(2+) transients in human embryonic kidney 293 cells expressing human alpha4beta2 or alpha3beta4 nAChRs, although some inhibition was noted for 5-HI, genistein, and TQS. In summary, our studies reveal two distinct alpha7 PAM profiles, which could offer unique opportunities for modulating alpha7 nAChRs in vivo and in the development of novel therapeutics for central nervous system indications.